Drug Approval | September 04, 2021
Reliance Life Science gets go-ahead for Phase I clinical trial for Covid-19 vaccine
The trial will be conducted across eight sites in Maharashtra
The trial will be conducted across eight sites in Maharashtra
The trial will be conducted across 10 sites in India
The Bidar API manufacturing facility of Sai Life Sciences has been on a path of significant expansion with its production capacity growing from 200KL in 2017 to 450KL
Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian market
The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract
At its meeting, the board also approved raising the company’s authorised share capital to Rs. 42.50 crores from Rs. 37.50 crores.
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
Subscribe To Our Newsletter & Stay Updated
